Horse-assisted physiotherapy for spinal muscular atrophy
Part of Brain & nervous system clinical trials.
This trial tests whether a special type of physiotherapy using horseback riding can help improve movement and function in children with spinal muscular atrophy. It is a gentle, supported therapy that may help with strength, balance, and coordination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Children aged 2 to 9 years
- Diagnosed with spinal muscular atrophy (SMA) type 1, 2, or 3
- Health has been stable for at least 6 months before starting
- No hip dislocation
- No allergy to horses or the stable environment
- No severe fear of horses that would prevent participation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different stiffness settings on a robotic exercise machine during arm and leg training for children with SMA. The goal is to see which setting works best to improve muscle strength and function.
This trial tests a new medicine called EXG001-307 for babies with spinal muscular atrophy (SMA) types 1 and 2. The goal is to see if it is safe and helps with muscle strength and breathing.
This study tests whether a combined program of home-based activities and hand training can help children with spinal muscular atrophy improve their movement and daily function. It is for children who can sit or walk with support and have been on stable medication for at least 6 months.
This trial tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) is safe and tolerable for people with spinal muscular atrophy (SMA). It may help improve muscle function by activating low motor neurons.
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
This trial tests a one-time gene therapy given through a vein to add a working SMN gene in children with spinal muscular atrophy (SMA). It mainly looks at safety first, and also checks early signs that treatment helps the disease.
Hear when a new Spinal Muscular Atrophy (SMA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.